Issue 6, 2013

Glucose conjugation for the specific targeting and treatment of cancer

Abstract

Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

Graphical abstract: Glucose conjugation for the specific targeting and treatment of cancer

Article information

Article type
Minireview
Submitted
11 dez 2012
Accepted
08 abr 2013
First published
08 abr 2013

Chem. Sci., 2013,4, 2319-2333

Glucose conjugation for the specific targeting and treatment of cancer

E. C. Calvaresi and P. J. Hergenrother, Chem. Sci., 2013, 4, 2319 DOI: 10.1039/C3SC22205E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements